Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Metagenomi Therapeutics reported first quarter 2026 financial results and key clinical updates, highlighting progress of its lead hemophilia A gene editing therapy MGX-001, on track for regulatory submissions this year and first-in-human trials in 2027. The company also announced the publication of novel CRISPR nuclease MG119-28 research in a prest…